Sai Life Sciences Limited, one of India's leading integrated contract research, development, and manufacturing organizations (CRDMOs), announced on May 11, 2026, that its Bidar campus now operates entirely on renewable power. The campus comprises Unit IV — the company's flagship API manufacturing facility — and Unit VI, its animal health API manufacturing facility. With this milestone, the Bidar site becomes the first facility within an Indian CRDMO to achieve 100% renewable electricity usage.

A Phased, Multi-Year Transition

The shift to full renewable power at the Bidar campus followed a structured, multi-year effort that progressively increased the share of renewable energy in the site's total consumption. The journey from partial to complete renewable power spanned over half a decade, reflecting a deliberate long-term approach to energy transition.

The progression of renewable energy adoption at the Bidar campus is outlined below:

How the 100% Target Is Met

The current energy mix at the Bidar site relies on two complementary mechanisms to ensure that the entire electricity consumption is backed by renewable sources:

• 97% of the site's electricity requirement is sourced directly from solar and wind power through Open Access renewable energy agreements.
• 3% is balanced through the procurement of International Renewable Energy Certificates (I-RECs).

The transition also combined long-term renewable power purchase agreements with direct investments in clean energy infrastructure, including a 2.7 MW wind project under a group captive model. In parallel, Sai Life Sciences implemented energy-efficiency initiatives through equipment upgrades, process optimization, and digital monitoring systems to improve operational performance and reduce overall energy demand.

Leadership Perspective

Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, commented on the achievement: "The medicines we help bring into the world serve patients for years, often decades. The infrastructure behind them should be built with the same horizon in mind. Decisions around energy and scale therefore have to anticipate a future where sustainability, resilience, and resource efficiency will increasingly define how global industry operates. This transition reflects that long-term view."

Broader Organisational Impact

The Bidar milestone is part of a wider sustainability effort across the organisation. The key outcomes at the organisational level are summarised below:

The Bidar milestone reflects Sai Life Sciences' broader approach to integrating scientific innovation, operational excellence, and long-term sustainability into the company's growth strategy. With operations across India, the UK, and the US, the company continues to advance its sustainability commitments alongside its core pharmaceutical services business.

Sai Life Sciences Limited has informed the stock exchanges about receipt of a Goods and Services Tax (GST) order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi. The order was passed on 29 April 2026 at 11:32 AM under Section 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka Goods and Services Tax Act, 2017.

Details of the GST Order

The order raises a demand concerning alleged excess availment of input tax credit in GSTR-3B than available in GSTR-2A for the financial year 2021-22. The tax authority has specified the following amounts:

Company's Response

According to the disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Life Sciences Limited stated that based on its assessment, an appeal will be filed against the order. The company expressed hope for a favourable outcome at the Tribunal level and indicated that it does not reasonably expect the said order to have any material financial impact on its operations.

The disclosure was signed by Runa Karan, Company Secretary & Compliance Officer, and submitted to both the National Stock Exchange of India Limited and BSE Limited on 30 April 2026.